NMD Pharma gets green light to proceed with neuromuscular target
Two months after getting data back from a successful phase I/IIa trial of lead candidate NMD670 in the myasthenia gravis indication, the US health authority is allowing the company to test the candidate against spinal atrophy.
by albert rønning-andersson, translated by daniel pedersen
Biotech company NMD Pharma is betting on more than one horse when it comes to its drug candidate, NMD670. In October, the candidate demonstrated proof of concept in a phase II study including 12 patients with the rare muscle disease known as myasthenia gravis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
NMD Pharma gets FDA orphan drug designation
For subscribers
Fujifilm Diosynth Biotechnologies to produce Argenx antibody
For subscribers
CHMP recommends approval of four drugs at November meeting
For subscribers
